Market closed · Next open: Monday 9:30 AM ET
Last update: Aug 21, 2026, 6:30 PM ET
TG Therapeutics, Inc.
$54.27 7.34% today
Market Closed

Why TG Therapeutics, Inc. (TGTX) stock moved

Updated Aug 22, 2026

TG Therapeutics, Inc. (TGTX) shares climbed 7.3% to $54.27 as of August 22, 2026, a significant gain from the prior close of $50.56. BestStocks flagged the session as a major change for TGTX. The move is tied to price move up. Below, we break down what changed for TGTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

TGTX climbed 7.3% to $54.27

TGTX climbed 7.3% in its latest session, moving from $50.56 to $54.27.

Material / EarningsMedium confidence
Rel. volume
2.3×
Very High
Vs peers
No comparable peers
Market cap
$8.3B
NASDAQ Capital Market
Analyst target
$81
+48.3% vs price
Price chart
Jul 22 – Aug 21
EFVEVEEEVEEEV$46$51$56Jul 22Jul 30Aug 6Aug 14Aug 21
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for TG Therapeutics, Inc. investors

For TG Therapeutics, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Strong 7.3% price move with conviction. Weighing against that: TG Therapeutics, Inc. (TGTX) moved -8.92% from $50.69 to $46.17 on 2026-08-03; TGTX moved -2.62% from $56.41 to $54.93 on 2026-07-16. Wall Street's consensus price target sits at $80.50, implying +48.3% upside from $54.27. BestStocks rates the overall signal quality medium (69/100). With earnings roughly 72 days out, the next report is the most likely near-term test of the move.

TGTX price reaction

TGTX last traded at $54.27, up $3.71 (+7.34%) from the previous close of $50.56. The session traded on 2.3× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $46.17 and $56.04, and it currently sits about 82% of the way up that band.

Bullish and bearish analyst opinions on TG Therapeutics, Inc. (TGTX)

The consensus analyst price target on TG Therapeutics, Inc. (TGTX) is $80.50, 48.3% above the recent $54.27. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on TGTX line up.

The bullish case

  • Wall Street's consensus price target of $80.50 implies +48.3% upside from $54.27.
  • The Street's most bullish target is $83.00 (+52.9%).
  • Material positive event.
  • Strong 7.3% price move with conviction.
  • Volume 2.3x average — institutional conviction.

The bearish case

  • TG Therapeutics, Inc. (TGTX) moved -8.92% from $50.69 to $46.17 on 2026-08-03.
  • TGTX moved -2.62% from $56.41 to $54.93 on 2026-07-16.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $81+48.3%
= 6 maintains
JP Morgan maintained Overweight · 2026-08-07
SEC filings watch
10-Q2026-08-05
Quarterly financial results
medium
8-K2026-08-03
Material event — review for impact
high
8-K2026-06-12
Material event — review for impact
high
8-K2026-06-03
Material event — review for impact
high
Peer context
TGTX+7.3%

Previous notable changes for TGTX

Material / Earnings2026-08-14+1.7%
TG Therapeutics, Inc. (TGTX) moved +3.11% from $47.27 to $48.74 on 2026-08-14. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move occurred on routine trading activity.
Material / Earnings2026-08-13-3.2%
TGTX moved -3.54% from $49.70 to $47.94 on 2026-08-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, indicating modestly elevated trading activity accompanying the decline.
Filings2026-08-05+2.3%
TG Therapeutics, Inc. (TGTX) filed a 10-Q on August 5, 2026, covering its most recent quarterly results.
Activity2026-08-05+2.3%
TG Therapeutics, Inc. (TGTX) moved +3.44% from $48.22 to $49.88 on August 5, 2026. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on volume near the 5-day average.
Upcoming catalysts & outlook
Next earnings
2026-11-02 (est.)
in 72 days
10-Q Filing (est.)
2026-11-04
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events

Frequently asked questions about TGTX

Why did TG Therapeutics, Inc. (TGTX) stock move?

TGTX climbed 7.3% to $54.27. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did TGTX stock rise?

TGTX gained 7.34% ($3.71) versus the prior close of $50.56, last trading at $54.27 on 2.3× average volume.

When is TG Therapeutics, Inc.'s next earnings date?

TGTX's next earnings report is estimated for 2026-11-02 — about 72 days away.

What is the analyst price target for TGTX?

The consensus analyst price target for TGTX is $80.50, about 48.3% above the current $54.27. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.

How BestStocks tracks TGTX

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for TGTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.